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Abstract Diabetic nephropathy is the main cause of
end-stage renal failure in the Western world. In diabetes,
metabolic and haemodynamic perturbations disrupt the
integrity of the glomerular filtration barrier, leading to ultra-
structural alterations of the glomeruli, including podocyte foot
process fusion and detachment, glomerular basement
membrane thickening, reduced endothelial cell glycocalyx,
and mesangial extracellular matrix accumulation and
glomerulosclerosis, ultimately leading to albuminuria and
end-stage renal disease. Many vascular growth factors, such
as angiopoietins, are implicated in glomerular biology. In
normal physiology angiopoietins regulate the function of the
glomerular filtration barrier. When they are dysregulated,
however, as they are in diabetes, they drive the cellular
mechanisms that mediate diabetic glomerular pathology.
Modulation of angiopoietins expression and signalling has
been proposed as a tool to correct the cellular mechanisms
involved in the pathophysiology of diabetic microvascular
disease, such as retinopathy in humans. Future work might
evaluate whether this novel therapeutic approach should be
extended to diabetic kidney disease.
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Abbreviations
ANGPT1 Angiopoietin 1
ANGPT2 Angiopoietin 2
GBM Glomerular basement membrane
TIE-2 Tyrosine kinase with immunoglobulin and
epidermal growth factor homology domain-2
VEGFA Vascular endothelial growth factor A
Introduction
Angiopoietins are vascular growth factors involved in
vasculogenesis and vascular repair. Two major isoforms
regulate vascular homeostasis, namely angiopoietin 1
(ANGPT1) and angiopoietin 2 (ANGPT2). ANGPT1, by
binding to its receptor tyrosine kinase with immunoglobulin
and epidermal growth factor homology domain-2 (TIE-2),
stabilises the vessel wall, while ANGPT2, by either
interacting with integrins or competing with ANGPT1-TIE-2
receptor binding (inhibiting ANGPT1-mediated TIE-2
phosphorylation), promotes vessel wall destabilisation and
favours, in the presence of vascular endothelial growth factor
A (VEGFA), endothelial cell proliferation and new vessel
formation.
Angiopoietins play an important role in the glomerular
capillaries in both physiology and disease. Glomerular
capillaries are unique in their structure: they are composed
of a fenestrated endothelium, which sits on a basement
membrane, and specialised epithelial cells (the podocytes),
which cover the external layers of the glomerular filter with
their interdigitating foot processes.
In recent years, work by different investigators has
highlighted the presence of an autocrine/paracrine network
consisting of angiopoietins and other vasoactive peptides
regulating the physiology of the glomerular capillaries in
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terms of blood flow and permeability of the vascular wall. An
imbalance in these vasoactive peptides promotes endothelial
dysfunction: one of the earliest mechanisms of vascular
chronic complications in diabetes.
This brief review focuses on the role of angiopoietins in
physiology and how an angiopoietin imbalance could
contribute to the pathophysiology of diabetic glomerulopathy.
Glomerular capillary function is regulated
by vasoactive peptides within an
epithelial–endothelial autocrine/paracrine system
The kidney glomerulus filters the blood to generate urine by
retaining cells and macromolecules. The adult glomerulus
consists of specialised capillaries composed of epithelial cells
(podocytes) separated from the endothelium and mesangium
by a thin glomerular basement membrane (GBM) [1]. All the
components of the glomerular filtration barrier participate in
the maintenance of the permselective properties of the
glomerular capillaries. Podocyte cells are composed of a
major cell body from which specialised foot processes depart
to interdigitate and form slit diaphragms [2], a specialised tight
junction (composed of proteins such as nephrin and podocin)
that represents one of the major size-selective barriers in the
glomerular capillaries preventing macromolecular passage
into the pre-urine [3, 4]. The glomerular endothelial cells are
fenestrated; the fenestrae are characterised by a unique
ultrastructure lacking diaphragms [5, 6] and facilitate high
permeability to water and small solutes [7]. The luminal side
of the glomerular endothelial cells is covered by a thin
glycocalyx consisting of proteoglycans [7], which are also
believed to contribute to the permselective properties of the
glomerular capillary [8]. The GBM also contributes to the
permeability of the glomerular capillary, and alteration of its
structure affects its ability to restrict both water [7] and protein
[9] filtration through the glomerular barrier.
Many recent studies have proposed a complex local
autocrine/paracrine network consisting of vascular growth
factors and vasoactive peptides secreted by glomerular cells
which exert their action by binding to their specific receptor
on podocytes and glomerular endothelial cells. The specific
balance of different growth factors such as angiopoietins and
VEGFA and their interaction have been recognised as crucial
mechanisms in the maintenance of a healthy glomerulus;
conversely, their imbalance has been shown to drive the early
pathological manifestations of diabetic glomerular disease.
Angiopoietins
Angiopoietins are vascular growth factors that promote the
formation of blood vessels. ANGPT1 and ANGPT2 are the
most studied angiopoietins [10]. ANGPT1 is the major
physiological ligand and activator (via phosphorylation) of
the TIE-2 receptor [11, 12]. ANGPT1 is extremely important
in early vasculature growth up to embryonic days 9.5–12.5
[13, 14]. Studies also suggest that ANGPT1 is important in
maintaining the stability (and permeability) of the mature
vasculature [15, 16]. This concept has, however, been
challenged by studies in mice with inducible global deletion
of Angpt1 from embryonic day 13.5 [14], in which animals
were viable and presented with no overt phenotype [14].
ANGPT2 has opposing actions to ANGPT1 and promotes
blood vessel wall destabilisation [17], not only by competitive
inhibition of the binding of ANGPT1 to TIE-2, hence
reducing TIE-2 activation and phosphorylation [17], but also
via integrin activation [18]. The biological effects of ANGPT2
appear to be dependent on the ambient levels of VEGFA:
ANGPT2 leads to vessel regression when VEGFA
expression/levels are low or absent, but participates in the
process of angiogenesis in the presence of high levels of
surrounding VEGFA [17]. Studies have shown that VEGFA
inhibits ANGPT1–TIE-2 signalling via TIE-2 shedding,
promoting, in concert with ANGPT2-mediated TIE-2
signalling inhibition, new vessel formation [19].
In the kidney glomerulus, Angpt1 is constitutively
expressed in podocytes [20, 21], while Angpt2 is transiently
detected during development in the mesangial cells [22], but is
then not expressed, or expressed at a very low level, in the
adult glomerulus in normal physiology. Tie2 (also known as
Tek) expression is localised in developing and adult mouse
glomerular capillaries mainly at the level of the endothelium
[20, 23], while some reports show its expression in mouse and
rat podocytes in vivo [21, 24].
Angiopoietins and diabetic glomerulopathy
The expression of angiopoietins in glomerular disease has
been investigated in different experimental animal models of
diabetes. In rats injected with streptozotocin, whole-kidney
Angpt1 and Angpt2 mRNA and protein increase at 4 weeks’
diabetes duration, but after 8 weeks ANGPT1 levels diminish,
while ANGPT2 remains elevated [25]. In another study,
whole glomeruli or glomerular endothelial cells isolated from
diabetic mice showed raised Angpt2 mRNA levels compared
with non-diabetic animals, while no changes were observed in
Angpt1 in the whole glomerulus [14].
Transgenic mouse studies have demonstrated that raised
Angpt2 leads to a phenotype similar to that seen in diabetic
glomerular disease. Indeed, inducible podocyte-specific
overexpression of Angpt2, increasing the ANGPT2/
ANGPT1 ratio in otherwise normal healthy adult mice, leads
to albuminuria and glomerular endothelial apoptosis, a
phenotype paralleled by downregulation of VEGFA and
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nephrin protein expression [26]. Similarly, ANGPT2 has been
shown to activate β1-integrin, resulting in destabilisation of
endothelial cell intercellular junctions via an increase in cell
contractility and alteration of pericellular matrix remodelling
[18].
Parallel work from our group has shown that, in the very
early stages of diabetic glomerulopathy (3 weeks’ diabetes
duration), glomerular Angpt1 mRNA decreases in diabetic
mice, with no significant changes in Angpt2 mRNA levels,
when compared with non-diabetic animals [24]. This apparent
acute effect of elevated circulating glucose levels was also
observed in vitro when Angpt1 mRNA was significantly
downregulated in high-glucose-treated podocytes compared
with normal-glucose-treated cells [24]. Overall, these
observations are consistent with the contention that an
increased ratio of ANGPT2/ANGPT1 could play a role in
the development and progression of glomerular disease in
diabetes (Fig. 1).
Studies using genetically modified mice have further
helped towards the understanding of angiopoietins in diabetic
glomerular disease. Global deletion of Angpt1 from
embryonic day 16.5 (to circumvent any adverse effects on
early vascular development) is paralleled, inmice at 20weeks’
diabetes duration, by increases in albuminuria and mesangial
matrix expansion and glomerulosclerosis [14], suggesting
that Angpt1 expression levels are important in the
pathophysiology of diabetic glomerular disease and could
confer protection against high-glucose-mediated glomerular
capillary injury, serving as a ‘brake’ on vascular lesions.
To further explore this possibility we restored the ANGPT1
deficiency found in early diabetic glomerulopathy using
transgenic mice overexpressing Angpt1, specifically in
the glomeruli, again with an inducible system [24].
Podocyte-specific ANGPT1 overexpression/repletion in the
adult diabetic mouse led to a reduction in albuminuria [24]
and downregulation of diabetes-induced VEGFA signalling.
The combination of high ANGPT1 levels and low VEGFA
signalling in diabetic nephropathy is likely to represent an
important mechanism that favours a more stable capillary
wall, a phenomenon that we described as paralleled by a
reduction in glomerular endothelial cell proliferation, as
seen in the early stages of diabetic nephropathy [27], and a
reduction in albumin excretion [24].
Overexpression/repletion of ANGPT1 in diabetic mice
increased the phosphorylation of endothelial nitric oxide
synthase on serine residue 1177 [24], an effect that may
increase nitric oxide [28] and lead to a more stable, less
permeable vascular wall [29, 30]. ANGPT1 repletion was also
accompanied by a reduction in diabetes-induced nephrin
phosphorylation [24], an event paralleled by reduced nephrin
degradation and improved foot processes in the podocyte
cytoskeleton/structure, leading to a more intact and functional
glomerular filtration barrier [31].
ANGPT2 mRNA was found to be elevated in isolated
glomeruli from patients with diabetes when compared with
live donor kidneys, while no change was observed in
ANGPT1 expression [24]. Importantly, poor glycaemic
control is paralleled by high circulating ANGPT2 levels in
patients with type 2 diabetes. ANGPT2 levels are also
associated with indexes of endothelial damage/dysfunction,
regardless of vascular disease [32]. Similarly, urinary
ANGPT2 levels are increased in patients with type 2 diabetes
with renal damage and are associated with albuminuria [33].
A recent study reported preliminary evidence that
ANGPT2 is an independent predictor of adverse renal
outcome in chronic kidney disease in both the general and
ANGPT1
ANGPT2
ANGPT1 overexpression
to normalise
ANGPT2/ANGPT1 ratio
ANGPT1 downregulation
in early diabetic glomerulopathy:
increased ANGPT2/ANGPT1 ratio
Normal physiology
ANGPT1
ANGPT1 ANGPT2
ANGPT2
Endothelial
survival
Vessel wall
stabilisation
Endothelial
sprouting/regression
Vessel wall destabilisation
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Fig. 1 ANGPT2/ANGPT1 imbalance is paralleled by capillary
destabilisation. ANGPT1 is downregulated in early diabetic kidney
disease, leading to diabetes-mediated angiopoietin imbalance
(ANGPT2 > ANGPT1); ANGPT2 excess results in proteinuria.
Repletion of ANGPT1 restores angiopoietin balance (ANGPT1>ANGPT2)
and, acting as a ‘brake’ on vascular lesions, prevents albuminuria
and glomerular structural lesions in the early phases of diabetic
glomerular disease. Red arrows indicate changes favouring progres-
sion towards vascular disease, green arrows point towards changes
stimulating a healthy vessel
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the diabetic population [34]. Of interest, raised ANGPT2
levels are associated with systemic markers of inflammation
in patients with chronic kidney disease and are predictors of
mortality [35]. For example, increased aortic stiffness is
known to be a powerful independent predictor of mortality
in individuals with type 2 diabetes [36], and recent work has
shown that plasma ANGPT2 is associated with arterial
stiffness in patients with chronic kidney disease [37].
Indeed, an imbalance in favour of ANGPT2 would promote
inflammation and fibrosis, withmacrophages as key players in
stimulating collagen-rich extracellular matrix synthesis by
vascular smooth muscle cells with stiffening of the vascular
wall [38].
Taking all these observations together, it is quite evident
that a tightly controlled angiopoietin TIE-2 receptor system is
required for the development and maintenance of a healthy
microvasculature and glomerular filtration barrier. Disruption
of the ANGPT2/ANGPT1 balance in favour of ANGPT2
leads to destabilisation of the capillary walls and an increase
in inflammation and vascular permeability, promoting
microvascular disease.
Manipulation of local and systemic angiopoietins could
represent an attractive therapeutic target for patients with
diabetic microvascular complications [39, 40]. Early studies
in patients with diabetes with macular oedema have shown
that administration of AKB-9778 (a vascular endothelial-
protein tyrosine phosphatase that promotes TIE-2 receptor
activation) for 4 weeks reduced macular oedema and
improved vision, without demonstrating any safety concerns
[41]. Future studies might address the role of TIE-2 activation
in diabetic glomerular disease.
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